Copanlisib - Aliqopa (USA)
According to the NCI website Copanlisib is a phosphoinositide 3-kinase (PI3K) inhibitorwith potential antineoplastic activity.
Indication according to the PDR:
- Used in adults with relapsed follicular lymphoma
Severe hyperglycemia and hypertension have been reported
Link to Physicians Desk Reference (PDR)
Link to European Medicines Agency (EMEA)